LGALS1 and neoplasm: Early in 2011, it was reported that the co-expression of Galectin-1 and CD146 is required for tumor vascularization in a human mesenchymal stem cell strain with significant angiogenic potential.106 In 2013, Jouve et al. reported that Galectin-1 binds to CD146 on endothelial cells, facilitating cell survival.107 In this report, they explained that CD146 glycosylation is mainly composed of branched N-glycans.